MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Suletud

2.06 2.49

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.98

Max

2.11

Põhinäitajad

By Trading Economics

Sissetulek

53M

-46M

Müük

-8.8M

56M

Aktsiakasum

-0.02

Kasumimarginaal

-82.429

Töötajad

570

EBITDA

127M

-21M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+176.62% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-216M

451M

Eelmine avamishind

-0.43

Eelmine sulgemishind

2.06

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. apr 2025, 23:53 UTC

Kuumad aktsiad

Stocks to Watch: Starbucks, Snap, Super Micro Computer, Seagate Technology

29. apr 2025, 23:06 UTC

Tulu

Prudential PLC 1Q New Business Profit Increases by 12%

29. apr 2025, 23:00 UTC

Tulu

America Movil's Posts Rise in 1Q Profit, Revenue

30. apr 2025, 00:00 UTC

Peamised uudised

Buffett's 'Woodstock for Capitalists' Draws Admirers From Around the Globe -- WSJ

29. apr 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Fears About U.S. Tariffs Ebb -- Market Talk

29. apr 2025, 23:43 UTC

Market Talk

Gold Consolidates; Signs of Easing in U.S. Tariffs' Impact May Weigh -- Market Talk

29. apr 2025, 23:41 UTC

Tulu

China Minsheng Banking 1Q Net Interest Income CNY24.87B Vs. CNY24.26B>1988.HK

29. apr 2025, 23:41 UTC

Tulu

China Minsheng Banking 1Q Operating Income CNY36.81B Vs. CNY34.27B>1988.HK

29. apr 2025, 23:41 UTC

Tulu

China Minsheng Banking 1Q Net CNY12.74B Vs. Net CNY13.45B >1988.HK

29. apr 2025, 23:24 UTC

Tulu

China Vanke 1Q Rev CNY37.99B Vs. CNY61.59B >000002.SZ

29. apr 2025, 23:24 UTC

Tulu

China Vanke: Increase in Investment Losses Also Hurt Results >000002.SZ

29. apr 2025, 23:24 UTC

Tulu

China Vanke 1Q Loss CNY6.25B Vs. Loss CNY361.97M >000002.SZ

29. apr 2025, 23:24 UTC

Tulu

China Vanke: Singificant Decline in Property Sales Weighed on Results >000002.SZ

29. apr 2025, 23:24 UTC

Tulu

China Vanke 1Q Loss Widened Significantly >000002.SZ

29. apr 2025, 23:15 UTC

Peamised uudised

UPS to Cut 20,000 Jobs After Amazon Breakup -- 2nd Update

29. apr 2025, 23:14 UTC

Tulu

China Eastern Airlines 1Q Loss CNY995.0M Vs. Loss CNY803.0M >0670.HK

29. apr 2025, 23:14 UTC

Tulu

China Eastern Airlines: Increased Competition in the Aviation Market Hurt Results >0670.HK

29. apr 2025, 23:14 UTC

Tulu

China Eastern Airlines 1Q Rev CNY33.41B Vs. CNY33.19B >0670.HK

29. apr 2025, 23:14 UTC

Tulu

China Eastern Airlines 1Q Loss Widened >0670.HK

29. apr 2025, 23:11 UTC

Tulu

China Southern Airlines Swung to Loss in 1Q>1055.HK

29. apr 2025, 23:11 UTC

Tulu

China Southern Airlines 1Q Rev CNY43.41B Vs. CNY44.60B >1055.HK

29. apr 2025, 23:11 UTC

Tulu

China Southern Airlines: Shift in Traveler Demographics, Competition From High-Speed Rail Networks Also Hurt Results >1055.HK

29. apr 2025, 23:11 UTC

Tulu

China Southern Airlines 1Q Loss CNY747.0M Vs. Net CNY756.0M >1055.HK

29. apr 2025, 23:11 UTC

Tulu

China Southern Airlines: CNY Depreciation, Global Supply Chain Constraints Among Factors Weighing on Results >1055.HK

29. apr 2025, 23:07 UTC

Tulu

Air China 1Q Rev CNY40.02B Vs. CNY40.07B >0753.HK

29. apr 2025, 23:07 UTC

Tulu

Air China 1Q Losses Widened>0753.HK

29. apr 2025, 23:07 UTC

Tulu

Air China 1Q Loss CNY2.04B Vs. Loss CNY1.67B >0753.HK

29. apr 2025, 23:02 UTC

Tulu

COSCO SHIPPING Energy Transportation: Weaker Earnings In International Oil Tanker Fleet Business Weighed on Results>1138.HK

29. apr 2025, 23:02 UTC

Tulu

COSCO SHIPPING Energy Transportation 1Q Net CNY707.70M Vs. Net CNY1.24B >1138.HK

29. apr 2025, 23:02 UTC

Tulu

COSCO SHIPPING Energy Transportation 1Q Rev CNY5.75B Vs. CNY5.84B >1138.HK

Võrdlus sarnastega

Hinnamuutus

Maravai LifeSciences Holdings Inc (Class A) Prognoos

Hinnasiht

By TipRanks

176.62% tõus

12 kuu keskmine prognoos

Keskmine 5.56 USD  176.62%

Kõrge 10 USD

Madal 2.5 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Maravai LifeSciences Holdings Inc (Class A) 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

10 ratings

6

Osta

4

Hoia

0

Müü

Tehniline skoor

By Trading Central

1.775 / 2.07Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Neutral Evidence

Pikk perspektiiv

Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.